KiOmed to receive an up front, ~$63.62M in development, regulatory & commercial milestones along with royalties. The companies collaborated to develop & commercialize KiOmedinevsOne for knee osteoarthritis, in China’s mainland, Macau & Taiwan
Hansoh to get an exclusive right & will be responsible to develop & commercialize KiOmedinevsOne & its future extensions in the territory while KiOmed obtains the right for KiOmedinevsOne in all other markets globally
KiOmedinevsOne is a carboxymethyl chitosan inj. & has been launched in the EU in 2021. In clinical studies, significant pain reduction within 2wks., following a single inj. of KiOmedinevsOne & 66% in WOMAC pain score with a long-lasting osteoarthritis symptom reduction for 6mos.
Ref: Businesswire | Image: Pfizer
